Cite
HARVARD Citation
Vlaar, A. et al. (2022). Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 10 (12), pp. 1137-1146. [Online].